Angela Achkar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Angela Achkar has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Elie Naous
Department of Medicine, Boston Medical Center Brighton, Boston, USA
4 shared publications - Joanna Mitri
Harvard Medical School , Boston, MA 02115 , USA
3 shared publications - Bertrand L. Jaber
Department of Medicine
1 shared publication - Christine Peloquin
Section of Rheumatology, School of Medicine, Boston UniversityChobanian & Avedisian , Boston, USA
1 shared publication - Jean W. Liew
J.W. Liew, MD, MS, Section of Rheumatology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts
1 shared publication - Juliano Alhaddad
Department of Medicine, Boston Medical Center Brighton, Boston, USA
1 shared publication
Latest Publications
- 11 September 2025
- Published by Springer Nature in Clinical Rheumatology
- p. 1-9
Targeted and biologic therapies and risk of total knee or hip replacement in axial spondyloarthritis and psoriatic arthritis
Background Axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) are chronic inflammatory diseases that often cause joint damage, potentially leading to joint replacement surgery. We assessed whether Janus kinase (JAK) inhibitors reduce the risk of total knee or hip replacement compared to nonsteroidal anti-inflammatory drugs (NSAIDs). Methods Using the Merative™ MarketScan® Commercial Database, we conducted a nested case–control study of adults aged 18–65 years with axSpA and/or PsA from October 2015 to December 2021. Medication exposure was categorized hierarchically using pharmacy and procedure claims, including JAK inhibitors, non-tumor necrosis factor inhibitor biologics (non-TNFi biologics), TNF inhibitors (TNFi), DMARDs, NSAIDs (referent), and none. Logistic regression with confounder adjustment assessed associations between medication class and joint replacement risk. Results Among 8855 eligible adults, 1771 cases of joint replacement were identified. JAK inhibitor use was not significantly associated with reduced odds of joint replacement compared to NSAIDs (odds ratio [OR] 0.67, 95% confidence interval [CI] 0.41–1.08). Non-TNFi biologic users (OR 0.66, 95% CI 0.53–0.82), TNFi users (OR 0.63, 95% CI 0.52–0.76), and DMARD users (OR 0.65, 95% CI 0.53–0.80) had lower odds of joint replacement than NSAID users. Conclusion We did not find conclusive evidence that relative to NSAIDs, JAK inhibitors prevent end-stage arthritis requiring surgery in axSpA and PsA; however, risk was reduced with use of non-TNFi biologics, TNFi, or DMARDs. Longer-term data are needed to understand the optimal utilization of JAK inhibitors in preventing end-stage arthritis in these conditions. Key Points • Axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) are chronic inflammatory diseases that often cause joint damage, potentially leading to joint replacement surgery. • In our study, although there was not conclusive evidence that JAK inhibitors prevent end-stage arthritis requiring surgery in axSpA and PsA relative to NSAIDs, we did find that risk was reduced with use of non-TNFi biologics, TNFi, or DMARDs. • Understanding the impacts of different medication classes, including Janus kinase (JAK) inhibitors and tumor necrosis factor inhibitors (TNFi) relative to nonsteroidal anti-inflammatory drugs (NSAIDs) may guide treatment decisions.
- 11 September 2025
- Published by Springer Nature in Clinical Rheumatology
- p. 1-9
Targeted and biologic therapies and risk of total knee or hip replacement in axial spondyloarthritis and psoriatic arthritis
Background Axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) are chronic inflammatory diseases that often cause joint damage, potentially leading to joint replacement surgery. We assessed whether Janus kinase (JAK) inhibitors reduce the risk of total knee or hip replacement compared to nonsteroidal anti-inflammatory drugs (NSAIDs). Methods Using the Merative™ MarketScan® Commercial Database, we conducted a nested case–control study of adults aged 18–65 years with axSpA and/or PsA from October 2015 to December 2021. Medication exposure was categorized hierarchically using pharmacy and procedure claims, including JAK inhibitors, non-tumor necrosis factor inhibitor biologics (non-TNFi biologics), TNF inhibitors (TNFi), DMARDs, NSAIDs (referent), and none. Logistic regression with confounder adjustment assessed associations between medication class and joint replacement risk. Results Among 8855 eligible adults, 1771 cases of joint replacement were identified. JAK inhibitor use was not significantly associated with reduced odds of joint replacement compared to NSAIDs (odds ratio [OR] 0.67, 95% confidence interval [CI] 0.41–1.08). Non-TNFi biologic users (OR 0.66, 95% CI 0.53–0.82), TNFi users (OR 0.63, 95% CI 0.52–0.76), and DMARD users (OR 0.65, 95% CI 0.53–0.80) had lower odds of joint replacement than NSAID users. Conclusion We did not find conclusive evidence that relative to NSAIDs, JAK inhibitors prevent end-stage arthritis requiring surgery in axSpA and PsA; however, risk was reduced with use of non-TNFi biologics, TNFi, or DMARDs. Longer-term data are needed to understand the optimal utilization of JAK inhibitors in preventing end-stage arthritis in these conditions. Key Points • Axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) are chronic inflammatory diseases that often cause joint damage, potentially leading to joint replacement surgery. • In our study, although there was not conclusive evidence that JAK inhibitors prevent end-stage arthritis requiring surgery in axSpA and PsA relative to NSAIDs, we did find that risk was reduced with use of non-TNFi biologics, TNFi, or DMARDs. • Understanding the impacts of different medication classes, including Janus kinase (JAK) inhibitors and tumor necrosis factor inhibitors (TNFi) relative to nonsteroidal anti-inflammatory drugs (NSAIDs) may guide treatment decisions.
- 11 July 2025
- Published by Springer Nature in Rheumatology International
- Vol. 45 (8) , 1-9
Risk of intracranial hemorrhage in anti-neutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids: a systematic review of case reports
The aim of our study is to investigate risk factors, clinical characteristics, laboratory findings, treatment strategies, and outcomes of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) presenting with central nervous system (CNS) involvement, with a focus on intracranial hemorrhage (ICH). A systematic review was conducted using PubMed, Cochrane, and EMBASE databases (through October 2024). Data from 47 patients with AAV-associated ICH (derived from 46 reports), were pooled and analyzed. The results were stratified by AAV subtype and outcome, and logistic regression analyses were used to identify determinants of outcome. Among the 47 patients with AAV-associated ICH, eosinophilic granulomatosis with polyangiitis was the most common AAV subtype (48.9%), followed by granulomatosis with polyangiitis (29.8%) and microscopic polyangiitis (14.9%). Intraparenchymal hemorrhage was the most frequent presentation (55.3%). Most patients (85.1%) were diagnosed with AAV at the time of ICH presentation, and 57.4% had not received prior immunosuppressive therapy. Glucocorticoid use before ICH was associated with higher mortality (P < 0.001), while treatment with cyclophosphamide or rituximab improved survival (P < 0.001). Age was identified as a significant predictor of mortality (P = 0.022). In conclusion, glucocorticoid use before the occurrence of ICH may worsen bleeding severity in patients with AAV. These findings highlight the importance of glucocorticoid-sparing strategies in managing CNS involvement in AAV, with cyclophosphamide or rituximab showing potential improved survival.
- 11 July 2025
- Published by Springer Nature in Rheumatology International
- Vol. 45 (8) , 1-9
Risk of intracranial hemorrhage in anti-neutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids: a systematic review of case reports
The aim of our study is to investigate risk factors, clinical characteristics, laboratory findings, treatment strategies, and outcomes of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) presenting with central nervous system (CNS) involvement, with a focus on intracranial hemorrhage (ICH). A systematic review was conducted using PubMed, Cochrane, and EMBASE databases (through October 2024). Data from 47 patients with AAV-associated ICH (derived from 46 reports), were pooled and analyzed. The results were stratified by AAV subtype and outcome, and logistic regression analyses were used to identify determinants of outcome. Among the 47 patients with AAV-associated ICH, eosinophilic granulomatosis with polyangiitis was the most common AAV subtype (48.9%), followed by granulomatosis with polyangiitis (29.8%) and microscopic polyangiitis (14.9%). Intraparenchymal hemorrhage was the most frequent presentation (55.3%). Most patients (85.1%) were diagnosed with AAV at the time of ICH presentation, and 57.4% had not received prior immunosuppressive therapy. Glucocorticoid use before ICH was associated with higher mortality (P < 0.001), while treatment with cyclophosphamide or rituximab improved survival (P < 0.001). Age was identified as a significant predictor of mortality (P = 0.022). In conclusion, glucocorticoid use before the occurrence of ICH may worsen bleeding severity in patients with AAV. These findings highlight the importance of glucocorticoid-sparing strategies in managing CNS involvement in AAV, with cyclophosphamide or rituximab showing potential improved survival.
- 7 March 2025
- Published by Elsevier in Endocrine Practice
- Vol. 31 (6) , 829-838
A Systematic Review on the Impact of Electronic Consultations on Diabetes Care
- 7 March 2025
- Published by Elsevier in Endocrine Practice
- Vol. 31 (6) , 829-838
A Systematic Review on the Impact of Electronic Consultations on Diabetes Care
- Open Access
Intermittent Fasting and Its Effects on Weight, Glycemia, Lipids, and Blood Pressure: A Narrative Review
Metabolic syndrome (MetS) has become a significant public health concern globally. Weight managementis crucial in controlling MetS risk factors, making energy balance and weight loss strategies important in nutrition recommendations. Intermittent fasting (IF) has gained traction as a dietary approach for weight management and cardiovascular risk reduction. However, the effects of IF on cardiovascular risk factors have been inconsistent in previous studies. This review aims to summarize the effects of various types of IF on body mass index (BMI), glycemia, lipid profile, and blood pressure, while providing insights into their clinical implications. A comprehensive search of interventional studies and meta-analyses was conducted, and the results were analyzed. The findings indicate that different types of IF lead to mixed effects. Time-restricted eating (TRE) and alternate-day fasting (ADF) consistently showed decreases in BMI, while the outcomes of intermittent energy restriction (IER) were more uncertain. The effects of IF on glycemia and lipid profile were also variable, with TRE and ADF generally showing positive results. However, the impact of IER remained inconsistent. More research is needed to understand the long-term effects and optimal implementation of IF for managing metabolic syndrome and cardiovascular risk factors.
Open AccessIntermittent Fasting and Its Effects on Weight, Glycemia, Lipids, and Blood Pressure: A Narrative Review
Metabolic syndrome (MetS) has become a significant public health concern globally. Weight managementis crucial in controlling MetS risk factors, making energy balance and weight loss strategies important in nutrition recommendations. Intermittent fasting (IF) has gained traction as a dietary approach for weight management and cardiovascular risk reduction. However, the effects of IF on cardiovascular risk factors have been inconsistent in previous studies. This review aims to summarize the effects of various types of IF on body mass index (BMI), glycemia, lipid profile, and blood pressure, while providing insights into their clinical implications. A comprehensive search of interventional studies and meta-analyses was conducted, and the results were analyzed. The findings indicate that different types of IF lead to mixed effects. Time-restricted eating (TRE) and alternate-day fasting (ADF) consistently showed decreases in BMI, while the outcomes of intermittent energy restriction (IER) were more uncertain. The effects of IF on glycemia and lipid profile were also variable, with TRE and ADF generally showing positive results. However, the impact of IER remained inconsistent. More research is needed to understand the long-term effects and optimal implementation of IF for managing metabolic syndrome and cardiovascular risk factors.
- 17 July 2023
- Published by Springer Nature in Journal of Racial and Ethnic Health Disparities
- Vol. 11 (5) , 2575-2582
Unspoken Consequences of Structural Racism in the USA: Diabetes and COVID-19
Objectives Black, Indigenous, and People of Color (BIPOC) are disproportionately impacted by the diabetes epidemic. This health inequity, aggravated by environmental, lifestyle, and genetic factors, has been further exacerbated by the COVID-19 pandemic. The increased risk of severe complications due to COVID-19 in BIPOC communities speaks to the importance of understanding the impacts of social and structural factors on health. This report aims to outline the connection between diabetes and vulnerability to COVID-19 through the lens of racism. Study Design Review of original report and subsequent modeling and interpretations. Methods We reviewed and analyzed original data in relation to health inequity, diabetes, COVID-19, and BIPOC. Results This holistic approach framed the disproportionate prevalence of diabetes and vulnerability to COVID-19 not just as a health disparity, but as a health inequity. Conclusion Defining the relationship between diabetes, vulnerability to COVID-19, and systems of advantage, such as racism, can further support the design of health interventions and policies that reduce the disproportionate impact of these diseases on the health of BIPOC communities.
- 17 July 2023
- Published by Springer Nature in Journal of Racial and Ethnic Health Disparities
- Vol. 11 (5) , 2575-2582
Unspoken Consequences of Structural Racism in the USA: Diabetes and COVID-19
Objectives Black, Indigenous, and People of Color (BIPOC) are disproportionately impacted by the diabetes epidemic. This health inequity, aggravated by environmental, lifestyle, and genetic factors, has been further exacerbated by the COVID-19 pandemic. The increased risk of severe complications due to COVID-19 in BIPOC communities speaks to the importance of understanding the impacts of social and structural factors on health. This report aims to outline the connection between diabetes and vulnerability to COVID-19 through the lens of racism. Study Design Review of original report and subsequent modeling and interpretations. Methods We reviewed and analyzed original data in relation to health inequity, diabetes, COVID-19, and BIPOC. Results This holistic approach framed the disproportionate prevalence of diabetes and vulnerability to COVID-19 not just as a health disparity, but as a health inequity. Conclusion Defining the relationship between diabetes, vulnerability to COVID-19, and systems of advantage, such as racism, can further support the design of health interventions and policies that reduce the disproportionate impact of these diseases on the health of BIPOC communities.
- Open Access
- 25 May 2020
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2020, 1-12
Differential Gender-Dependent Patterns of Cardiac Fibrosis and Fibroblast Phenotypes in Aging Mice
Aging is characterized by physiological changes within the heart leading to fibrosis and dysfunction even in individuals without underlying pathologies. Gender has been shown to influence the characteristics of cardiac aging; however, gender-dependent cardiac fibrosis occurring with age remains largely not elucidated. Thus, broadening our understanding of this phenomenon proves necessary in order to develop novel anti-fibrotic strategies in the elderly. In this study, we aim to characterize cardiac fibrosis and cardiac fibroblast (CF) populations in aged male and female mice. Echocardiography revealed eccentric hypertrophy with left ventricular dilatation in the aged male versus concentric hypertrophy with left posterior wall thickening in the female, with preserved cardiac function in both groups. Reactive fibrosis was evidenced in the myocardium and epicardium of the aged female mice hearts whereas perivascular and replacement ones where present in the male heart. Collagen I was predominant in the aged male heart whereas collagen III was the main component in the female heart. CFs in the aged male heart were mainly recruited from resident PDGFRα+ populations but not derived from epicardium as evidenced by the absence of epicardial progenitor transcription factors Tcf21, Tbx18 and Wt1. Our results present a paradigm for gender-dependent cardiac fibrosis and the origins of CFs with age. This sets forth to revisit cardiac anti-fibrotic management according to the gender in the elderly and to explore novel therapeutic targets.
- 25 May 2020
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2020, 1-12
Open AccessDifferential Gender-Dependent Patterns of Cardiac Fibrosis and Fibroblast Phenotypes in Aging Mice
Aging is characterized by physiological changes within the heart leading to fibrosis and dysfunction even in individuals without underlying pathologies. Gender has been shown to influence the characteristics of cardiac aging; however, gender-dependent cardiac fibrosis occurring with age remains largely not elucidated. Thus, broadening our understanding of this phenomenon proves necessary in order to develop novel anti-fibrotic strategies in the elderly. In this study, we aim to characterize cardiac fibrosis and cardiac fibroblast (CF) populations in aged male and female mice. Echocardiography revealed eccentric hypertrophy with left ventricular dilatation in the aged male versus concentric hypertrophy with left posterior wall thickening in the female, with preserved cardiac function in both groups. Reactive fibrosis was evidenced in the myocardium and epicardium of the aged female mice hearts whereas perivascular and replacement ones where present in the male heart. Collagen I was predominant in the aged male heart whereas collagen III was the main component in the female heart. CFs in the aged male heart were mainly recruited from resident PDGFRα+ populations but not derived from epicardium as evidenced by the absence of epicardial progenitor transcription factors Tcf21, Tbx18 and Wt1. Our results present a paradigm for gender-dependent cardiac fibrosis and the origins of CFs with age. This sets forth to revisit cardiac anti-fibrotic management according to the gender in the elderly and to explore novel therapeutic targets.